ADVOCATE (2021) — Trial Summary
ADVOCATE (2021): The ADVOCATE trial evaluated avacopan, an oral selective C5a receptor inhibitor, as a treatment for ANCA-associated vasculitis, compared to prednisone.
References
- Jayne DRW, Merkel PA, Schall TJ, et al. Avacopan for the Treatment of ANCA-Associated Vasculitis. N Engl J Med. 2021;384(7):599-609.